A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma

Introduction We present a case of novel coronavirus disease‐2019 that underwent combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. Case presentation A 50‐year‐old man complained of anorexia and weight loss. Contrast‐enhanced computed tomography revealed a solid ma...

Full description

Bibliographic Details
Main Authors: Yu Kijima, Tomokazu Shimizu, Shinya Kato, Eri Sekido, Kana Kano, Makoto Toguchi, Toshihide Horiuchi, Hiroshi Toma, Shoichi Iida, Toshio Takagi
Format: Article
Language:English
Published: Wiley 2022-03-01
Series:IJU Case Reports
Subjects:
Online Access:https://doi.org/10.1002/iju5.12412
Description
Summary:Introduction We present a case of novel coronavirus disease‐2019 that underwent combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. Case presentation A 50‐year‐old man complained of anorexia and weight loss. Contrast‐enhanced computed tomography revealed a solid mass of 57 mm in diameter with cysts in the right kidney, along with liver, lung, and multiple bone metastases. Computed tomography‐guided biopsy of the right kidney was performed, and a diagnosis of clear cell renal cell carcinoma was made. Three weeks after nivolumab and ipilimumab administration, the patient contracted coronavirus disease‐2019. Anticoagulation therapy (dalteparin) was administered for 4 days once infection was confirmed, after which dexamethasone was administered for 10 days. The patient survived without experiencing worsened respiratory symptoms. Conclusion We administered nivolumab and ipilimumab combination therapy as treatment for metastatic renal cell carcinoma. No side effects or immune‐related adverse events were observed for a short time.
ISSN:2577-171X